Key result
Younger patients (18-39 years) with Brucella endocarditis had significantly worse follow-up outcomes compared to those aged 40-59 years (OR 0.277; 95% CI 0.103-0.748; P=0.011).
Why the study?
Brucella endocarditis is a fatal complication and the primary cause of death in human brucellosis, but follow-up outcomes and their determinants needed systematic evaluation.
Systematic Review (n=207)
Odds Ratio: 0.277 (95% CI 0.103–0.748)
p-value: p=0.011
Brucella endocarditis has significant short- and long-term relapse and mortality rates, with younger patients (18-39 years) experiencing worse outcomes.
Alerts clinicians to higher short- and long-term risks in younger Brucella endocarditis patients; extends observational data on age-specific outcomes.
Brucella endocarditis is a fatal complication and the most frequent cause of death for human brucellosis. This study aimed to systematically review the literature on the follow-up outcomes of Brucella endocarditis and analyze the determinants affecting the follow-up outcomes. The databases PubMed, Web of Science, Embase, and Cochrane were searched using keywords and suitable combinations. All studies reporting the follow-up outcomes of Brucella endocarditis were included. Finally, a total of 76 studies (207 patients), including cases or case series, were included. The event rate for patients who underwent short- and long-term follow-up was 12.0% (2 relapsed and 1 died) and 8.1% (6 relapsed and 8 died), respectively. The differences in outcomes between different age groups (18–39, 40–59, and ≥60) were significant (P < 0.05, P = 0.035). The outcomes of the 18–39 age group were worse than those of the 40–59 age group (OR, 0.277; 95% CI, 0.103–0.748; P = 0.011). Accordingly, follow-up (both short- and long-term follow-up) is essential for Brucella endocarditis patients, especially for younger patients (18–39 years) in the first 6 months after treatment. The burden of Brucella endocarditis related complications were immense. Further studies are needed to explore age-based epidemiology of Brucella endocarditis and the exact influencing factors of the follow-up outcomes.
No takes yet. Share an insight, caveat, or question.
Li et al. (2021) conducted a systematic review in Brucella endocarditis (n=207). Age 18-39 years vs. Age 40-59 years was evaluated on Follow-up outcomes (OR 0.277, 95% CI 0.103-0.748, p=0.011). Younger patients (18-39 years) with Brucella endocarditis had significantly worse follow-up outcomes compared to those aged 40-59 years (OR 0.277; 95% CI 0.103-0.748; P=0.011).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: